You are here: Industry Insights > nintedanib

News List

Mount Sinai, Boehringer Ingelheim to Evaluate Nintedanib for Fibrosing ILD Following COVID-19 americanpharmaceuticalreview
December 07, 2020
The Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.
ISMMS, Boehringer Ingelheim to test nintedanib for treating pulmonary fibrosis post-COVID-19 infectio expresspharma
November 23, 2020
The primary endpoint of the study is percent change in forced vital capacity, a measurement of lung function, compared to baseline over six months.
Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection prnewswire
November 20, 2020
The Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim today announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.
Boehringer Ingelheim Enrolls First Patient to Evaluate nintedanib for Pediatric Fibrosing ILD americanpharmaceuticalreview
August 17, 2020
Boehringer Ingelheim announced the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing ...
DCGI approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung diseas expresspharma
May 21, 2020
Approval is based on the SENSCIS study which showed Nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD).
Boehringer Ingelheim gets EC approval for nintedanib to treat SSc-ILD pharmaceutical-business-review
April 26, 2020
Boehringer Ingelheim has secured approval from the European Commission (EC) for its nintedanib to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adult patients.
FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD) drugs
September 09, 2019
The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated...
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD worldpharmanews
March 27, 2019
Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA.
Boehringer Ingelheim files for regulatory approval of nintedanib pharmaceutical-technology
March 20, 2019
Boehringer Ingelheim has filed regulatory submissions with the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).
Anticancer drug nintedanib found to be effective against malignant pleural mesothelioma europeanpharmaceuticalreview
May 22, 2018
Researchers have found that nintedanib shows promising effectiveness in halting the growth of human malignant pleural mesothelioma in preclinical models.